Analytical Data
-
Gene name
CT47A1
- Application
-
Alternative Names
CT47A1; CT47A2; CT47A3; CT47A4; CT47A5; CT47A6; CT47A7; CT47A8; CT47A9; CT47A10; CT47A11; CT47A12
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NM_173571.2/
-
Expression Region
Met1~Thr288
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT47A1, a member of the CT (cancer/testis) antigen family, has garnered attention in cancer immunotherapy research due to its restricted expression pattern. Primarily expressed in testicular germ cells and various cancerous tissues, CT47A1 is not present in normal somatic tissues, making it an ideal candidate for targeted therapeutic strategies. The investigation of CT47A1 is rooted in its potential role as a biomarker for cancer diagnosis and prognosis, particularly in malignancies such as melanoma, lung cancer, and breast cancer. Its unique expression profile suggests that it could serve as a target for cancer vaccines and adoptive T-cell therapies, highlighting its relevance in the development of personalized immunotherapeutic approaches. Furthermore, understanding the molecular mechanisms regulating CT47A1 expression may provide insights into tumorigenesis and immune evasion strategies utilized by cancer cells. Recent studies have focused on characterizing the immunogenicity of CT47A1, aiming to develop novel vaccines that induce robust immune responses against tumors expressing this antigen. Overall, research on CT47A1 not only contributes to the broader understanding of cancer biology but also holds promise for advancing treatment options through immunotherapy.
